Finance

Lists
D4S:FRA
Daiichi Sankyo Co Ltd
€ १६.१५
-२.७१%
(-०.४५) 1D
सेप्टेम्बर १८, २२:००:०० GMT+२  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for D4S...
Open
€ १६.०९
High
€ १६.१५
Low
€ १६.०९
Mkt. cap
३५.२८ अरब
Avg. vol.
७७.००
Volume
१०.००
52-wk high
€ २३.७५
52-wk low
€ १२.६९
No. of employees
२० हजार
Open
€ १६.०९
High
€ १६.१५
Low
€ १६.०९
Mkt. cap
३५.२८ अरब
Avg. vol.
७७.००
Volume
१०.००
52-wk high
€ २३.७५
52-wk low
€ १२.६९
No. of employees
२० हजार
News stories
From web sources and news partners
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent. Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees२०.२ हजार
Founded२००५ सेप्टेम्बर २८
HeadquartersChuo City, टोक्यो, जापान
Sector-
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
५.०१ खरब
५.५८ खरब
५.९० खरब
५.७५ खरब
Cost of goods sold
१.५६ खरब
१.१८ खरब
३.०२ खरब
१.२४ खरब
Cost of revenue
१.५६ खरब
१.१८ खरब
३.०२ खरब
१.२४ खरब
Research and development expenses
१.१२ खरब
१.२२ खरब
१.२६ खरब
१.१५ खरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.८९ खरब
२.२८ खरब
१.५४ खरब
२.५० खरब
Operating expense
२.९७ खरब
३.५० खरब
२.७९ खरब
३.६५ खरब
Total operating expenses
४.५३ खरब
४.६९ खरब
५.८२ खरब
४.९० खरब
Operating income
४७.५२ अरब
८९.५४ अरब
७.७७ अरब
८५.१० अरब
Other non operating income
-
-
६.२२ अरब
-२०.०० लाख
EBT including unusual items
५७.७८ अरब
१.०७ खरब
२२.४४ अरब
९१.३४ अरब
EBT excluding unusual items
५७.७८ अरब
१.०७ खरब
७.८४ अरब
९१.३४ अरब
Income tax expense
१२.४६ अरब
२०.१० अरब
-३९.८४ अरब
२२.७० अरब
Effective tax rate
२१.५७%
१८.८३%
-१७७.५२%
२४.८६%
Other operating expenses
-३.५६ अरब
-४.९० करोड
-९०.८० करोड
-६.९० करोड
Net income
४५.३१ अरब
८६.६३ अरब
६२.२८ अरब
६८.६४ अरब
Net profit margin
९.०५%
१५.५२%
१०.५६%
११.९४%
Earnings per share
-
-
-
-
Interest and investment income
१०.६८ अरब
१९.०८ अरब
३७.७० करोड
९.७४ अरब
Interest expense
-८३.४० करोड
-२.१६ अरब
-१८.९१ अरब
-३.२३ अरब
Net interest expenses
९.८४ अरब
१६.९१ अरब
-१८.५३ अरब
६.५१ अरब
Depreciation and amortization charges
-
-
-
-
EBITDA
६६.४१ अरब
१.०९ खरब
२८.८९ अरब
१.०७ खरब
Gain or loss from assets sale
१.७५ अरब
५७.३० करोड
८.५० अरब
१८.०० करोड
AI content may include mistakes. Learn more
Google एपहरू